These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 7526527)

  • 41. Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy.
    Hall MC; Troncoso P; Pollack A; Zhau HY; Zagars GK; Chung LW; von Eschenbach AC
    Urology; 1994 Dec; 44(6):869-75. PubMed ID: 7527168
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer.
    Hanlon AL; Diratzouian H; Hanks GE
    Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):297-303. PubMed ID: 12023133
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictors of metastatic disease after prostate brachytherapy.
    Forsythe K; Burri R; Stone N; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):645-52. PubMed ID: 22137025
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer.
    Zagars GK; Pollack A; Kavadi VS; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 May; 32(2):293-306. PubMed ID: 7538498
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center experience, 1988-1995.
    Preston DM; Bauer JJ; Connelly RR; Sawyer T; Halligan J; Leifer ES; McLeod DG; Moul JW
    Urology; 1999 Jan; 53(1):131-8. PubMed ID: 9886602
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer - focus on overall survival.
    Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
    Radiat Oncol; 2017 Jun; 12(1):98. PubMed ID: 28615058
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
    D'Amico AV; Moul JW; Carroll PR; Sun L; Lubeck D; Chen MH
    J Natl Cancer Inst; 2003 Sep; 95(18):1376-83. PubMed ID: 13130113
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis.
    Lee WR; Hanks GE; Schultheiss TE; Corn BW; Hunt MA
    J Clin Oncol; 1995 Feb; 13(2):464-9. PubMed ID: 7531222
    [TBL] [Abstract][Full Text] [Related]  

  • 52. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
    Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis.
    Shipley WU; Thames HD; Sandler HM; Hanks GE; Zietman AL; Perez CA; Kuban DA; Hancock SL; Smith CD
    JAMA; 1999 May; 281(17):1598-604. PubMed ID: 10235152
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic significance of DNA ploidy in patients with stage II and stage III colon carcinoma: a prospective flow cytometric study.
    Lanza G; Gafà R; Santini A; Maestri I; Dubini A; Gilli G; Cavazzini L
    Cancer; 1998 Jan; 82(1):49-59. PubMed ID: 9428479
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer.
    Kuban DA; el-Mahdi AM; Schellhammer PF
    Int J Radiat Oncol Biol Phys; 1995 May; 32(2):307-16. PubMed ID: 7538499
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
    Stege R; Grande M; Carlström K; Tribukait B; Pousette A
    Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy.
    Sartor CI; Strawderman MH; Lin XH; Kish KE; McLaughlin PW; Sandler HM
    Int J Radiat Oncol Biol Phys; 1997 Jul; 38(5):941-7. PubMed ID: 9276358
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients.
    Oudard S; Banu E; Scotte F; Banu A; Medioni J; Beuzeboc P; Joly F; Ferrero JM; Goldwasser F; Andrieu JM
    Ann Oncol; 2007 Nov; 18(11):1828-33. PubMed ID: 17846024
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The prognostic value of deoxyribonucleic acid flow cytometric analysis in stage D2 prostatic carcinoma.
    Miller J; Horsfall DJ; Marshall VR; Rao DM; Leong SY
    J Urol; 1991 Jun; 145(6):1192-6. PubMed ID: 2033691
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dose response in prostate cancer with 8-12 years' follow-up.
    Hanks GE; Hanlon AL; Epstein B; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):427-35. PubMed ID: 12243818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.